Credit Suisse’s Core Laboratories CLB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
$983K Buy
57,525
+2,082
+4% +$32.7K ﹤0.01% 2280
2023
Q4
$979K Sell
55,443
-34,510
-38% -$695K ﹤0.01% 2344
2023
Q3
$2.16M Sell
89,953
-20,767
-19% -$510K ﹤0.01% 1793
2023
Q2
$2.57M Buy
110,720
+33,087
+43% +$748K ﹤0.01% 1751
2023
Q1
$1.71M Buy
77,633
+1,414
+2% +$33.1K ﹤0.01% 1976
2022
Q4
$1.54M Buy
76,219
+14,852
+24% +$288K ﹤0.01% 2037
2022
Q3
$828K Sell
61,367
-2,351
-4% -$39.6K ﹤0.01% 2456
2022
Q2
$1.26M Buy
63,718
+20,721
+48% +$550K ﹤0.01% 2229
2022
Q1
$1.36M Buy
42,997
+4,731
+12% +$133K ﹤0.01% 2334
2021
Q4
$853K Sell
38,266
-4,232
-10% -$110K ﹤0.01% 3439
2021
Q3
$1.18M Sell
42,498
-9,878
-19% -$301K ﹤0.01% 3205
2021
Q2
$2.04M Sell
52,376
-4,145
-7% -$149K ﹤0.01% 2847
2021
Q1
$1.63M Buy
56,521
+11,919
+27% +$407K ﹤0.01% 2972
2020
Q4
$1.18M Buy
44,602
+3,624
+9% +$74K ﹤0.01% 3220
2020
Q3
$625K Buy
40,978
+7,436
+22% +$156K ﹤0.01% 3256
2020
Q2
$682K Sell
33,542
-5,293
-14% -$94.9K ﹤0.01% 3135
2020
Q1
$401K Sell
38,835
-14,052
-27% -$393K ﹤0.01% 3245
2019
Q4
$1.99M Buy
52,887
+1,160
+2% +$52.1K ﹤0.01% 2601
2019
Q3
$2.41M Buy
51,727
+1,648
+3% +$76.6K ﹤0.01% 2328
2019
Q2
$2.62M Sell
50,079
-3,122
-6% -$183K ﹤0.01% 2253
2019
Q1
$3.67M Sell
53,201
-11,965
-18% -$802K ﹤0.01% 1954
2018
Q4
$3.89M Buy
65,166
+4,321
+7% +$373K ﹤0.01% 1764
2018
Q3
$7.05M Sell
60,845
-3,058
-5% -$345K 0.01% 1477
2018
Q2
$8.06M Buy
63,903
+2,311
+4% +$281K 0.01% 1368
2018
Q1
$6.67M Sell
61,592
-14,651
-19% -$1.62M 0.01% 1515
2017
Q4
$8.35M Buy
76,243
+9,919
+15% +$990K 0.01% 1408
2017
Q3
$6.55M Buy
66,324
+7,910
+14% +$767K 0.01% 1553
2017
Q2
$5.92M Sell
58,414
-11,210
-16% -$1.21M 0.01% 1527
2017
Q1
$8.04M Buy
69,624
+11,678
+20% +$1.36M 0.01% 1334
2016
Q4
$6.96M Buy
57,946
+4,623
+9% +$512K 0.01% 1433
2016
Q3
$5.99M Sell
53,323
-1,116
-2% -$129K 0.01% 1523
2016
Q2
$6.75M Sell
54,439
-9,264
-15% -$1.12M 0.01% 1432
2016
Q1
$7.16M Sell
63,703
-5,350
-8% -$556K 0.01% 1304
2015
Q4
$7.51M Buy
69,053
+8,584
+14% +$983K 0.01% 1314
2015
Q3
$6.04M Sell
60,469
-5,368
-8% -$584K 0.01% 1422
2015
Q2
$7.51M Buy
65,837
+1,226
+2% +$149K 0.01% 1441
2015
Q1
$6.75M Sell
64,611
-15,095
-19% -$1.61M 0.01% 1443
2014
Q4
$9.59M Buy
79,706
+13,971
+21% +$1.84M 0.01% 1316
2014
Q3
$9.62M Buy
65,735
+4,999
+8% +$772K 0.01% 1311
2014
Q2
$10.1M Sell
60,736
-21,921
-27% -$3.9M 0.01% 1389
2014
Q1
$16.4M Buy
82,657
+3,146
+4% +$594K 0.02% 935
2013
Q4
$15.2M Buy
79,511
+27,863
+54% +$5.19M 0.01% 991
2013
Q3
$8.74M Sell
51,648
-18,118
-26% -$2.81M 0.01% 1221
2013
Q2
$10.6M Buy
+69,766
New +$9.89M 0.01% 1101

Other funds holding CLB

Credit Suisse's CLB Position: Q1 2024 in Review

Credit Suisse increased its Core Laboratories (CLB) stake by 3.8% in Q1 2024, buying an estimated $32.7K and bringing the position to 57,525 shares worth $983K. The position accounts for ﹤0.01% of the portfolio, ranked #2280.

Credit Suisse first reported a position in CLB in Q2 2013 and has held it in 44 quarters since. The position peaked at $16.4M in Q1 2014. 197 funds tracked by Wall St. Rank hold CLB as of Q1 2024.

  • Credit Suisse held 57,525 shares of Core Laboratories worth $983K as of Q1 2024.
  • Credit Suisse bought 2,082 Core Laboratories shares in Q1 2024, an estimated $32.7K.
  • Core Laboratories made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2280 holding.
  • Credit Suisse first reported a position in Core Laboratories in Q2 2013 and has held it in 44 quarters since.
  • Credit Suisse's Core Laboratories position peaked at $16.4M in Q1 2014.
  • 197 funds tracked by Wall St. Rank held Core Laboratories as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.